Roche’s (VTX:ROG) Avastin (bevacizumab) and Tecentriq (atezolizumab) will be studied in combination, without chemotherapy, in a investigator-sponsored Phase II study in first-line non-small-cell lung cancer that will begin at the end of the summer, according to a source familiar with the situation.
The trial will enroll approximately 300 patients and will use progression-free survival (PFS) as its primary endpoint, the source noted. The study will take place at multiple sites across Europe, he added. The study will recruit patients without selecting for PD-L1 expression.
With positive readouts for checkpoint inhibitor combinations such as Tecentriq/Avastin/chemotherapy and Merck’s (NYSE:MRK) Keytruda (pembrolizumab)/chemotherapy, there is uncertainty regarding which combination is optimal, the source noted. Additional trials are necessary to elucidate the optimal combination in first-line NSCLC, he explained.
The first-line NSCLC market has been valued by analysts as between USD 10-12bn. Roche have not reported the initiation of the study in SEC filings.